A randomized, double-blind, vehicle-controlled, multicenter trial of topically administered LDE225 cream [0.75% bid] to evaluate clearance of Basal Cell Carcinoma in adult patients with Nevoid Basa...

Mise à jour : Il y a 5 ans
Référence : EUCTR2010-019856-30

A randomized, double-blind, vehicle-controlled, multicenter trial of topically administered LDE225 cream [0.75% bid] to evaluate clearance of Basal Cell Carcinoma in adult patients with Nevoid Basal Cell Carcinoma Syndrome

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective is: • To demonstrate the superiority of topical LDE225 versus vehicle in terms of treatment success in patients with NBCCS, 4 weeks after LDE225 treatment for 8 weeks or 12 weeks.


Critère d'inclusion

  • Basal Cell Carcinoma in adult patients with Nevoid Basal Cell Carcinoma Syndrome

Liens